Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer. Therefore, we studied whether addition of gemcitabine to erlotinib...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bartholomeusz, Chandra, Yamasaki, Fumiyuki, Saso, Hitomi, Kurisu, Kaoru, Hortobagyi, Gabriel N., Ueno, Naoto T.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ivyspring International Publisher 2011
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3157020/
https://ncbi.nlm.nih.gov/pubmed/21850211
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller